The fight over state PBM laws will continue after Supreme Court denial
The Supreme Court recently declined to wade into a fight over a state’s regulation of pharmacy benefit managers. But legal experts say it likely won’t be the last time the broader issue makes its way ...
View ArticleTrump's tax cut law expands orphan drug exclusions, could upend 340B program
President Donald Trump on July 4 signed into law his wide-ranging tax cuts and reconciliation package, including an expansion of orphan drug protections from Medicare negotiations, and nearly $1...
View ArticleDoctors sue RFK Jr., HHS over changes to Covid-19 vaccine schedule
A group of organizations representing thousands of doctors nationwide sued HHS Secretary Robert F. Kennedy Jr. over his decision to change Covid-19 vaccine recommendations for kids and pregnant women....
View ArticleNovartis maps launch of malaria drug for newborns after Swiss approval
Novartis has secured approval in Switzerland for its malaria treatment for small babies and infants, with plans to launch the first-of-its-kind drug on a not-for-profit basis in certain regions. The...
View ArticleSCG Cell Therapy gets China thumbs-up for study of potentially curative HBV...
A Singaporean biotech said it has the green light to start a Phase 1/2 trial of a cell therapy designed to cure chronic hepatitis B infection in what it claims is an industry first. ...
View ArticleShell company Concentra has found its rhythm, with Cargo Therapeutics as its...
Kevin Tang's Concentra Biosciences has inked its fifth buyout of the season, this time forging a deal to take out cell therapy biotech Cargo Therapeutics. This marks back-to-back weeks in which the...
View ArticleStartup raises $45M for universal flu vaccines made with mRNA
It’s not an easy time to raise money for vaccine development, especially shots that rely on mRNA technology. But against all odds, one startup has cinched $45 million to begin testing an experimental...
View ArticleQuanterix closes $127M Akoya deal after competing bid
Quanterix has completed its acquisition of Akoya Biosciences, following interest from a third-party bidder who threatened to torpedo the deal that has a total enterprise value of $127 million. The...
View ArticleProKidney's stock shoots higher after mixed Phase 2 data
Kidney disease drug developer ProKidney vaulted above $1 per share this morning, despite mixed open-label Phase 2 data. The company is studying whether its lead program, a cell therapy called...
View ArticleThe highest-paid pharma and biotech CEOs of 2024
The typical CEO of a public biopharma company made $4.73 million in 2024, a 40% jump from last year’s median figure. But a handful of CEOs hauled in much larger paydays. Endpoints News compiled data ...
View ArticleRecursion takes full rights to rare genetic disorder drug; CStone...
Plus, news about Basilea, BARDA, Inventiva and CTTQ: Recursion buys full rights to oral drug: The AI-driven biotech, which recently restructured, acquired the full rights to REV102, an ...
View ArticleIn first half of 2025, novel drug approvals are in line with previous years
Thousands of FDA staff departures since April have sparked concerns within the pharma industry that novel drug approval deadlines might slip. But in the first six months of 2025, the approval numbers...
View ArticleOtsuka’s Taiho reports Phase 3 fail for Duchenne muscular dystrophy drug
An Otsuka subsidiary said Tuesday that its experimental therapy for Duchenne muscular dystrophy has failed its Phase 3 primary endpoint in a group of ambulatory patients in Japan. Taiho Pharmaceutical
View ArticleTrump hints at tariff grace period for pharma companies to onshore manufacturing
President Donald Trump said pharmaceutical companies will have a grace period of at least a year to move their manufacturing to the US before facing tariffs on their drugs. The new detail disclosed...
View Article'CRISPR Cures' center launches to make custom gene editing therapies
Scientists seeking to make personalized gene editing therapies a reality for more people have launched a new initiative to develop cures for the rarest of diseases left behind by drug companies. ...
View ArticleSupreme Court halts California order that blocked RFK Jr. from reorganizing HHS
HHS Secretary Robert F. Kennedy Jr. can go ahead with some of his plans to downsize the federal health agencies after the US Supreme Court suspended a district court order on Tuesday. The high court ...
View ArticleNimble radiopharma biotech Actithera gets $75M to enter the clinic
For a year and a half, Actithera was essentially a one-man show. As the radiopharma startup's only employee, CEO Andreas Goutopoulos had to hustle for 10 months to get the first term sheet for a ...
View ArticleFDA approves new dosing of Lilly’s Alzheimer’s drug Kisunla to lower brain...
Eli Lilly’s new Alzheimer’s drug is off to a slow start, but the Indianapolis drugmaker hopes that an update to the treatment’s prescription label may help build confidence among doctors and patients ...
View ArticleMerck to buy respiratory drugmaker Verona Pharma for $10B
Merck is boosting its respiratory portfolio with a $10 billion takeover of commercial-stage drugmaker Verona Pharma, the companies said Wednesday morning. It signals Merck’s ongoing appetite for large...
View Article
